Introduction: Antiplatelet therapy combining aspirin and clopidogrel is considered to be a key intervention for acute ischemic minor stroke (AIMS) and transient ischemic attack (TIA). However, the interindividual variability in response to clopidogrel resulting from the polymorphisms in clopidogrel metabolism-related genes has greatly limited its efficacy. To date, there are no reports on individualized antiplatelet therapy for AIMS and TIA based on the genetic testing and clinical features. Therefore, we conducted this randomized controlled trial (RCT) to validate the hypothesis that the individualized antiplatelet therapy selected on the basis of a combination of genetic information and clinical features would lead to better clinical outcomes compared to the standard care based only on clinical features in patients with AIMS or TIA.
We will submit the results of this trial for publication in a peer-reviewed journal.
Trial registration number: ChiCTR1800019911

Strengths and limitations of this study
This is a well-designed study to assess the efficacy and safety of individualized This study will help clinicians predict and estimate the risk of clopidogrel resistance in patients with AIMS or TIA, and then take corresponding measures to reduce the risk of stroke recurrence.
One limitation is that we mainly focus on the CYP2C19 genotype (*2, *3 and *17 alleles), which might neglect the potential impact of other alleles.
Another limitation is that the trial implementation is not multi-centered, which might limit its generalisability. AIMS or TIA have a high risk of subsequent ischemic events, especially during the first 90 days after the cerebrovascular event. 1 During this acute phase, there is still a risk of previous ischemic tissue, with ruptured plaques in a state of high thrombus formation and high platelet activation, which may lead to more severe acute instability events. 2 Therefore, antiplatelet therapy is considered to be a key intervention for AIMS and TIA at present.
Clopidogrel is one of the commonly used anti-platelet drugs in clinic, which is recommended for the secondary prevention of ischemic stroke. The Clopidogrel in
High-Risk Patients with Acute Nondisabling Cerebrovascular Events (CHANCE) trial
reported that compared with aspirin alone, the combination of clopidogrel with aspirin decreased the risk of stroke among patients with AIMS or TIA who can be treated within 24 hours after the onset of symptoms. 3 However, there is interindividual variability in response to clopidogrel, which leads to the result that a large number of subsequent strokes still occur despite clopidogrel treatment and even among those treated with dual-antiplatelet agents. 4 Those patients who have poor response to clopidogrel against platelet aggregation and are therefore at greater risk of ischemic events are suffering from clopidogrel resistance. 5 Clopidogrel resistance is an important cause of failure in the prevention and treatment of patients with partial ischemic stroke, and will greatly increase the recurrence of ischemic stroke. To date, the mechanisms related to variability in clopidogrel responsiveness are not fully elucidated. 6 Mounting evidence have showed that genetic factors may play a crucial role in mediating clopidogrel resistance. 7 As clopidogrel is a prodrug that requires hepatic cytochrome P450 (CYP) for its conversion into an active metabolite 8 , polymorphisms of its encoded gene CYP2C19 have been identified as strong predictors of clopidogrel nonresponsiveness. 9 Among them, CYP2C19 loss-of-function genotype (*2 and/or *3 alleles) is found to be related to low responsiveness to clopidogrel, which is a risk factor for ischemic events, whereas the presence of gain-of function CYP2C19 allele (*17) is associated with a high platelet inhibition and increased risk of bleeding. 10 The genetic substudy of the CHANCE trial also showed that only in patients with AIMS or TIA who did not carry the CYP2C19 loss-of-function alleles, the combined treatment of 11 This study provided evidence to support the genetic testing that may allow clinicians to personalize antiplatelet therapy, especially in East Asian patient populations for whom the prevalence of CYP2C19 loss-of-function allele is high. 11, 12 To date, the clinical factors and genetic factors affecting clopidogrel responses have not reached a consistent conclusion. Besides, most of the study endpoints are cardiovascular events, and the research on cerebrovascular events is lacking. For example, Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines recommend that non-carriers of CYP2C19 loss-of-function alleles patients with acute coronary syndrome (ACS) continue to take clopidogrel 75 mg daily, and carriers are advised to increase the dose of clopidogrel or switch to other antiplatelet agents such as ticagrelor. 13 Wallentin et al. researched on the genetics of the CYP2C19 gene polymorphism in patients with ACS and found that compared with clopidogrel, treatment with ticagrelor significantly reduced the death rate from vascular causes in patients with CYP2C19 loss of function alleles. 10 However, for patients with AIMS or TIA with clopidogrel resistance, it is unclear whether there will be more clinical benefit when switching to ticagrelor. Based on the above, we conducted this randomized controlled trial to validate the hypothesis that the individualized antiplatelet therapy selected on the basis of a combination of genetic information and a patient's clinical features would lead to better clinical outcomes compared to the standard care based only on clinical features in patients with AIMS or TIA.
METHOD Design
The design of study is shown in Fig. 1 
Patient population
Patients are included into this study if they meet all the following criteria: 1). age of 18 years or older; 2). diagnosis of an AIMS or TIA; AIMS is defined as a sudden focal neurological dysfunction caused by vascular causes, and score of 3 or less at the time of randomization on the National Institutes of Health Stroke Scale (NIHSS; scores range from 0 to 42, with higher scores indicating greater deficits). 3 TIA is defined as a transient episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischemia, without acute infarction; 14 3). onset of the AIMS or TIA symptoms less than 72 h.
Patients are excluded from study participation if one of the following criteria is met: 1) hemorrhage; other conditions, such as vascular malformation, trauma, tumor, abscess, degenerative neurologic disease or other major nonischemic brain disease; 2) systemic infectious diseases, autoimmune diseases, severe heart, liver and kidney diseases; 3) any contraindication to the use of aspirin or P2Y12 receptor antagonists; 4) prior knowledge of the patients' CYP2C19*2, CYP2C19*3 or CYP2C19*17 genotype; 5) ongoing treatment in another observational or registry randomized trial; 6) an inability to provide informed consent or unavailability for follow-up.
Based on the PLATO trial and PHARMCLO trial exclusion criteria, ticagrelor is contraindicated in patients: 1) with active pathological bleeding; 2) with a history of intracranial bleeding; 3) requiring dialysis, 4) taking oral anticoagulant therapy that could not be stopped; 5) with known clinically important thrombocytopenia; 6) receiving fibrinolytic therapy within the previous 24 hours; and 7) taking concomitant therapy with strong CYP3A inhibitors or inducers. 15, 16 Patients and public involvement Patients in this trial will be not involved in the designment, recruitment and conduction of the study. All patients will be provided informed consent and clopidogrel genes of patients in pharmacogenetic group will be detected as soon as possible after the random assignment. The individual genetic information will inform the corresponding participant. We will not perform the structural evaluation on study patients' burden in RCTs. Both pharmacogenetic group and standard group receive a loading dose of 100-300 mg of aspirin and 300 mg of clopidogrel on day 1, followed by a dose of 100 mg of aspirin per day on days 2 to 365. Patients randomly assigned to the pharmacogenetic group receive a dose of 75 mg clopidogrel per day (UM and EM group), 150 mg clopidogrel per day (IM group) and ticagrelor 90 mg twice daily (PM group) on days 2 to 21, which can be further adjusted in combination with clinical features. While for standard group, the P2Y12 receptor antagonist is selected by the clinician according to the clinical features of the patients. The clinical features include age, weight, ischemic risk, prior history of stroke/TIA, bleeding risk, intracranial bleeding, active bleeding, history of bleeding, anemia, diabetes or chronic kidney disease.
Randomization and treatments
Primary outcomes
The primary endpoint for this trial is a new stroke event (ischemic or hemorrhagic) that happens within one year. Ischemic stroke is defined as a sudden focal neurological dysfunction caused by vascular causes, duration ≥ 24 hours, or neurological dysfunction due to imaging and clinical symptoms caused by bloody infarction rather than cerebral hemorrhage found by imaging examination. Hemorrhagic stroke is 
Secondary outcomes
The secondary endpoint was the composite of the primary endpoint plus new clinical vascular event (ischemic stroke, hemorrhagic stroke, myocardial infarction, or vascular death). The definition of vascular death is adapted from the CHANCE trial. 3 Briefly, vascular death is defined as death resulting from stroke (ischemic or hemorrhagic), systemic hemorrhage, myocardial infarction, congestive heart failure, pulmonary embolism, sudden death, or arrhythmia.
Safety assessments
Safety endpoint is a major bleeding event, according to the definitions in 
Sample size
Based on data from the One-year outcomes of the CHANCE trial 19 , a primary endpoint (ischemic or hemorrhagic stroke) rate of 10.6% is originally assumed at one year following randomization. The sample size is calculated based on the assumption that the cumulative event rate of the primary outcome in the standard group after one year would be 15%. Given a relative risk reduction in the pharmacogenomic group of 5%, 95% power and a two-sided type I error of 0.05, the calculated sample size is 1,134 patients in each group. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y The distributions of baseline characteristics are compared between two study groups using T test. Proportions are used for categorical variables and continuous variables will be reported as median (inter-quartile range). Cox proportional-hazard model is used to estimate the hazard ratio and 95% confidence intervals relating to the primary and secondary outcomes. Schoenfeld residuals test is used to confirm the proportional hazards assumption for the Cox regression model. For estimating the cumulative incidence of endpoints during the 1-year follow-up, we perform the Kaplan-Meier analyses by means of Aalen-Johansen estimator. And Fine-Gray model is used to test the significance of the differences between the sub-distribution of the hazards. Values of P < 0.05 are considered statistically significant.
Statistical analyses
DISCUSSION
Currently, clopidogrel combined with aspirin has become the preferred treatment for patients with AIMS or TIA. 20 However, the pharmacokinetics of clopidogrel could be influenced by metabolic status. Poor metabolizers will cause insufficient antiplatelet effect and impaired clinical benefit. 21 At present, the mechanisms of clopidogrel resistence are not fully elucidated and evidences from the genetic substudy of CHANCE trail showed the correlation between CYP2C19 polymorphisms with clopidogrel nonresponsiveness. For patients with AIMS or TIA treated with clopidogrel and aspirin, CYP2C19 loss-of-function alleles carriers were prone to have increased risk for subsequent stroke and composite vascular events compared with noncarriers. 11 Although these genetic associations with clinical benefits have been widely replicated and the sample sizes are large enough to be predictive in the clinical setting, there are few examples using pharmacogenetic data concerning clopidogrel metabolism to guide clinical practice. [22] [23] [24] Thus, genotype-guided antiplatelet therapy may be regarded as a prospective alternative approach to personalized treatment in AIMS or TIA.
Given the fact that clopidogrel is currently the only antiplatelet agent approved for use in ischemic mild stroke or TIA with aspirin and there are indeed differences in reactivity between individuals, varying the dose of clopidogrel or shifting to new antiplatelet agents based on genetic datas may be alternatives, but it has not been adequately evaluated. 25 This RCT will provide evidence for the assumption that using pharmacogenetic data to select P2Y12 receptor antagonists can be successfully incorporated into the clinical care of patients with AIMS or TIA. The selection of a Competing interests None declared.
Patient consent Obtained.
Ethics approval Ethics committee, Yangpu Hospital, Tongji University School of Medicine, China. We will submit the results of this trial for publication in a peer-reviewed journal.
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Strengths and limitations of this study
This is a study to assess the efficacy and safety of individualized antiplatelet therapy selected on the basis of a combination of genetic information and a patient's clinical features in patients with AIMS or TIA.
The results from this randomized study will provide new evidence of the efficacy of individualized antiplatelet therapy on the basis of genetic information for AIMS or TIA.
This study will help clinicians predict and estimate the risk of clopidogrel resistance in patients with AIMS or TIA, and then take corresponding measures to reduce the risk of stroke recurrence.
Another limitation is that the trial implementation is not multi-centered and only Chinese population are included, which might limit its generalisability. Therefore, antiplatelet therapy is considered to be a key intervention for AIMS and TIA at present.
High-Risk Patients with Acute Nondisabling Cerebrovascular Events (CHANCE) trial
reported that compared with aspirin alone, the combination of clopidogrel with aspirin decreased the risk of stroke among patients with AIMS or TIA who can be treated within 24 hours after the onset of symptoms. 3 However, there is interindividual variability in response to clopidogrel, which leads to the result that a large number of subsequent strokes still occur despite clopidogrel treatment and even among those treated with dual-antiplatelet agents. 4 Compared with the inhibition of platelet aggregation expected, poor inhibition using antiplatelet therapy is referred to high ontreatment platelet reactivity (HPR). 5 Those patients who show HPR to clopidogrel and are therefore at greater risk of ischemic events are suffering from clopidogrel resistance. 5, 6 Clopidogrel resistance is an important cause of failure in the prevention and treatment of patients with partial ischemic stroke, and will greatly increase the recurrence of ischemic stroke. To date, the mechanisms related to variability in clopidogrel responsiveness are not fully elucidated. 7 Mounting evidence have shown that genetic factors may play a crucial role in mediating clopidogrel resistance. 8 As clopidogrel is a prodrug that requires hepatic cytochrome P450 (CYP) for its conversion into an active metabolite 9 , polymorphisms of its encoded gene CYP2C19 have been identified as strong predictors of clopidogrel nonresponsiveness. 10 Among them, CYP2C19 loss-of-function genotype (*2 and/or *3 alleles) is found to be related to low responsiveness to clopidogrel, which is a risk factor for ischemic events, whereas the presence of gain-of function CYP2C19 allele (*17) is associated with a high platelet inhibition and increased risk of bleeding. 11 The genetic 
METHOD Design
Patient population
Patients are included into this study if they meet all the following criteria: 1). age of 18 years or older; 2). diagnosis of an AIMS or TIA; AIMS is defined as a sudden focal neurological dysfunction caused by vascular causes, and score of 3 or less at the time of randomization on the National Institutes of Health Stroke Scale (NIHSS; scores range from 0 to 42, with higher scores indicating greater deficits). 3 TIA is defined as a transient episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischemia, without acute infarction; 15 3). onset of the AIMS or TIA symptoms less than 72 h.
Patients are excluded from study participation if one of the following criteria is met:
1) hemorrhage; other conditions, such as vascular malformation, trauma, tumor, abscess, degenerative neurologic disease or other major nonischemic brain disease; 2) systemic infectious diseases, autoimmune diseases, severe heart, liver and kidney diseases; 3) any contraindication to the use of aspirin or P2Y12 receptor antagonists; 4) prior knowledge of the patients' CYP2C19*2, CYP2C19*3 or CYP2C19*17 genotype; 5) ongoing treatment in another observational or registry randomized trial; 6) an inability to provide informed consent or unavailability for follow-up.
Based on the PLATO trial and PHARMCLO trial exclusion criteria, ticagrelor is contraindicated in patients: 1) with active pathological bleeding; 2) with a history of intracranial bleeding; 3) requiring dialysis, 4) taking oral anticoagulant therapy that could not be stopped; 5) with known clinically important thrombocytopenia; 6) receiving fibrinolytic therapy within the previous 24 hours; and 7) taking concomitant therapy with strong CYP3A inhibitors or inducers. 16, 17 Patients and public involvement
Patients in this trial will not be involved in the design, recruitment and conduction of the study. Clopidogrel genes of patients in pharmacogenetic group will be detected as soon as possible after the random assignment. The individual genetic information and the corresponding anti-platelet aggregation drug adjustment regimen will be disseminated to study participants as soon as possible after the gene detection. Satisfaction of the intervention and the burden of involvement in this RCT will be assessed as part of the evaluation.
Randomization and treatments
Patients are consented and randomized in a 1:1 ratio to pharmacogenetic or standard group as soon as feasible after the diagnosis of AIMS or TIA is made and no later 72 
Primary efficacy endpoint
The primary efficacy endpoint for this trial is a new stroke event (ischemic or hemorrhagic) that happens within one year. Ischemic stroke is defined as a sudden focal Hemorrhagic stroke is defined as acute extravasation of blood into the brain parenchyma or subarachnoid space with associated neurologic symptoms.
Secondary efficacy endpoint
The secondary efficacy endpoint is analyzed as the individual or composite outcomes of the new clinical vascular event (ischemic stroke, hemorrhagic stroke, myocardial infarction, or vascular death). The definition of vascular death is adapted from the CHANCE trial. 3 Briefly, vascular death is defined as death resulting from stroke (ischemic or hemorrhagic), systemic hemorrhage, myocardial infarction, congestive heart failure, pulmonary embolism, sudden death, or arrhythmia.
Safety assessments
Sample size
Based on data from the One-year outcomes of the CHANCE trial with a primary endpoint (ischemic or hemorrhagic stroke) rate of 10.6% 20 , and considering that the time point when patients start to receive treatments in our study is later than that in the CHANCE trial, we estimate a higher incidence of primary efficacy endpoint in the standard group and define it as 15%. As we expect an absolute risk reduction of 5% in the pharmacogenomic group, so we define it as 10%. Given a 5% missed follow-up rate, 95% power and a two-sided type I error of 0.05, the calculated sample size is 1, 191 patients in each group. 
DISCUSSION
Currently, clopidogrel combined with aspirin has become the preferred short-term treatment for patients with AIMS or TIA for many clinicians. 21 However, the pharmacokinetics of clopidogrel could be influenced by metabolic status. Poor metabolizers will cause insufficient anti-platelet effect and impaired clinical benefit. 22 At present, the mechanisms of clopidogrel resistence are not fully elucidated and evidences from the genetic substudy of CHANCE trail showed the correlation between CYP2C19 polymorphisms with clopidogrel nonresponsiveness. For patients with AIMS or TIA treated with clopidogrel and aspirin, CYP2C19 loss-of-function alleles carriers were prone to have increased risk for subsequent stroke and composite vascular events compared with noncarriers. 12 Although these genetic associations with clinical benefits have been widely replicated and the sample sizes are large enough to be predictive in the clinical setting, there are few examples using pharmacogenetic data concerning clopidogrel metabolism to guide clinical practice. [23] [24] [25] Regarding to cardiovascular diseases, mounting evidence have shown that for patients with CYP2C19 loss-of-function alleles, obtaining genotype data early after percutaneous coronary intervention (PCI) and thus making genotype-guided personalized antiplatelet therapeutic regimen could reduce risks for major adverse cardiovascular events (MACE). 26, 27 Thus, genotype-guided antiplatelet therapy may be regarded as a prospective alternative approach to personalized treatment in AIMS or TIA. We will submit the results of this trial for publication in a peer-reviewed journal.
Strengths and limitations of this study
The results from this RCT will provide new evidence of the efficacy of individualized antiplatelet therapy on the basis of genetic information for AIMS or TIA.
The study is mainly focused on the CYP2C19 genotype (*2, *3 and *17 alleles), which might neglect the potential impact of other alleles.
The trial implementation is not multi-centered and only Chinese population are included, which might limit its generalisability. Therefore, antiplatelet therapy is considered to be a key intervention for AIMS and TIA at present.
High-Risk Patients with Acute Nondisabling Cerebrovascular Events (CHANCE) trial
reported that compared with aspirin alone, the combination of clopidogrel with aspirin decreased the risk of stroke among patients with AIMS or TIA who can be treated within 24 hours after the onset of symptoms. 3 However, there is interindividual variability in response to clopidogrel, which leads to the result that a large number of subsequent strokes still occur despite clopidogrel treatment and even among those treated with dual-antiplatelet agents. 4 Compared with the inhibition of platelet aggregation expected, poor inhibition using antiplatelet therapy is referred to high ontreatment platelet reactivity (HPR). 5 Those patients who show HPR to clopidogrel and are therefore at greater risk of ischemic events are suffering from clopidogrel resistance. 5, 6 Clopidogrel resistance is an important cause of failure in the prevention and treatment of patients with partial ischemic stroke, and will greatly increase the recurrence of ischemic stroke. To date, the mechanisms related to variability in clopidogrel responsiveness are not fully elucidated. 7 Mounting evidence have shown that genetic factors may play a crucial role in mediating clopidogrel resistance. 8 As clopidogrel is a prodrug that requires hepatic cytochrome P450 (CYP) for its conversion into an active metabolite 9 , polymorphisms of its encoded gene CYP2C19 have been identified as strong predictors of clopidogrel nonresponsiveness. 10 Among them, CYP2C19 loss-of-function genotype (*2 and/or *3 alleles) is found to be related to low responsiveness to clopidogrel, which is a risk factor for ischemic events, whereas the presence of gain-of function CYP2C19 allele (*17) is associated with a high platelet inhibition and increased risk of bleeding. 11 The genetic 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
METHOD Design
The design of study is shown in Fig. 1 systemic infectious diseases, autoimmune diseases, severe heart, liver and kidney diseases; 3) any contraindication to the use of aspirin or P2Y12 receptor antagonists; 4) prior knowledge of the patients' CYP2C19*2, CYP2C19*3 or CYP2C19*17 genotype; 5) ongoing treatment in another observational or registry randomized trial; 6) an inability to provide informed consent or unavailability for follow-up.
Based on the PLATO trial and PHARMCLO trial exclusion criteria, ticagrelor is contraindicated in patients: 1) with active pathological bleeding; 2) with a history of intracranial bleeding; 3) requiring dialysis, 4) taking oral anticoagulant therapy that could not be stopped; 5) with known clinically important thrombocytopenia; 6) receiving fibrinolytic therapy within the previous 24 hours; and 7) taking concomitant therapy with strong CYP3A inhibitors or inducers. 16, 17 Patients and public involvement Patients in this trial will not be involved in the design, recruitment and conduction of the study. Clopidogrel genes of patients in pharmacogenetic group will be detected as soon as possible after the random assignment. The individual genetic information and the corresponding anti-platelet aggregation drug adjustment regimen will be disseminated to study participants as soon as possible after the gene detection. 
Primary efficacy endpoint
Secondary efficacy endpoint
Safety assessments
Sample size
Statistical analyses
The distributions of baseline characteristics are compared between two study groups using T test. Proportions and χ2 test are used for categorical variables and continuous variables will be reported as median (inter-quartile range). Cox proportional-hazard model is used to estimate the hazard ratio and 95% confidence intervals relating to the primary and secondary outcomes. Schoenfeld residuals test is used to confirm the proportional hazards assumption for the Cox regression model. For estimating the cumulative incidence of endpoints during the 1-year follow-up, we perform the Kaplan-Meier analyses by means of Aalen-Johansen estimator. And Fine-Gray model is used to test the significance of the differences between the sub-distribution of the hazards. Values of P < 0.05 are considered statistically significant.
DISCUSSION
Currently, clopidogrel combined with aspirin has become the preferred short-term treatment for patients with AIMS or TIA for many clinicians. 21 However, the pharmacokinetics of clopidogrel could be influenced by metabolic status. Poor metabolizers will cause insufficient anti-platelet effect and impaired clinical benefit. 22 At present, the mechanisms of clopidogrel resistence are not fully elucidated and evidences from the genetic substudy of CHANCE trail showed the correlation between CYP2C19 polymorphisms with clopidogrel nonresponsiveness. For patients with AIMS or TIA treated with clopidogrel and aspirin, CYP2C19 loss-of-function alleles carriers were prone to have increased risk for subsequent stroke and composite vascular events compared with noncarriers. 12 Although these genetic associations with clinical benefits have been widely replicated and the sample sizes are large enough to be predictive in the clinical setting, there are few examples using pharmacogenetic data concerning clopidogrel metabolism to guide clinical practice. [23] [24] [25] Regarding to cardiovascular diseases, mounting evidence have shown that for patients with CYP2C19 loss-of-function alleles, obtaining genotype data early after percutaneous coronary intervention (PCI) and thus making genotype-guided personalized antiplatelet therapeutic regimen could reduce risks for major adverse cardiovascular events (MACE). 26, 27 Thus, genotype-guided antiplatelet therapy may be regarded as a prospective alternative approach to personalized treatment in AIMS or TIA. Given the fact that clopidogrel is currently the most widely used antiplatelet agent for AIMS or TIA with aspirin and there are indeed differences in reactivity among individuals, varying the dose of clopidogrel or shifting to new antiplatelet agents based on genetic datas may be alternatives, but it has not been adequately evaluated. 28 The ongoing Platelet Reactivity in Acute Non-disabling Cerebrovascular Events (PRINCE) study intends to investigate whether the combination of ticagrelor and aspirin is superior to the combination of clopidogrel and aspirin in reducing the 90-day HPR for AIMS or TIA, especially for carriers of CYP2C19 loss-of-function allele. 29 The interim results of PRINCE trial have shown that although ticagrelor could significantly reduce HPR better than clopidogrel, there were no significant differences between the two groups in reducing stroke and the composite endpoint events. 30 More future randomized studies of genotype-guided antiplatelet therapy may be of value. Thus, this RCT will provide evidence for the assumption that using pharmacogenetic data to select P2Y12 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r p e e r r e v i e w o n l y 
Funding
Roles and responsibilities
（P3-P4）
(P4)
(P7) Sample size 14 Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations Recruitment 15 Strategies for achieving adequate participant enrolment to reach target sample size
Methods: Assignment of interventions (for controlled trials)
Allocation:
Sequence generation 16a Method of generating the allocation sequence (eg, computergenerated random numbers), and list of any factors for stratification.
To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions 20c Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)
Methods: Monitoring
Data monitoring 21a Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
